DataString Consulting Company Logo
DataString Consulting Company Logo
Niraparib Tosylate Monohydrate Market
Home»Recent Reports»Niraparib Tosylate Monohydrate

Niraparib Tosylate Monohydrate Market Size, Growth Trends, and Forecast 2025-2034

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802375, Published - June 2025

Segmented in Product Form (Powder, Granule, Tablet), Application (Chemotherapy, Maintenance Treatment, Targeted Therapy, Others), Distribution Channel, Purity Grade and Production Method

Share this report:

Global Niraparib Tosylate Monohydrate
Market Outlook

The market, for Niraparib Tosylate Monohydrate was estimated at $1.6 billion in 2024; and it is anticipated to increase to $2.5 billion by 2030 with projections indicating a growth to around $3.5 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 7.5% over the forecast period. Niraparib Tosylate Monohydrate is experiencing growth with a substantial Compound Annual Growth Rate (CAGR) within its specific market segment It is increasingly sought after due to its crucial role in the life sciences field and its significant contribution to various strategies for treating oncology conditions This uptrend is driven by its extensive utilization in addressing ovarian cancer across diverse demographic groups and age ranges The continuous relevance of Niraparib Tosylate Monohydrate is amplified by the rising investments in research and development as well, as the adoption of innovative healthcare solutions globally


The use of Niraparib Tosylate Monohydrate as an inhibitor of Poly (AD P Ribose ) Polymerase (PAR P ) enzymes is crucial, for the advancement of specific cancer treatments. This compound is mainly employed in creating anti cancer medications and has shown encouraging outcomes in addressing challenging ovarian cancers.


Market Size Forecast & Key Insights

2019
$1.6B2024
2029
$3.3B2034

Absolute Growth Opportunity = $1.7B

The Niraparib Tosylate Monohydrate market is projected to grow from $1.6 billion in 2024 to $3.3 billion in 2034. This represents a CAGR of 7.5%, reflecting rising demand across Oncological Therapies, Maintenance Therapy and Research & Development.

The Niraparib Tosylate Monohydrate market is set to add $1.7 billion between 2024 and 2034, with manufacturer targeting Maintenance Treatment & Targeted Therapy Application projected to gain a larger market share.

With Rising prevalence of ovarian cancer, and Technological advancements in cancer treatment, Niraparib Tosylate Monohydrate market to expand 106% between 2024 and 2034.

Opportunities in the Niraparib Tosylate Monohydrate Market

Leveraging Technological Advancements

New developments in drug formulation technology present possibilities for the wider use of Niraparib Tosylate Monohydrate due to its improved bioavailability and effectiveness being a key focus area, within the pharmaceutical industry landscape.

Strategic Collaboration and Partnership and Catering to Evolving Consumer Needs

The promising capabilities of Niraparib Tosylate Monohydrate in the treatment of cancers present opportunities for forging strategic alliances and partnerships within the medical field. Rising demand for efficient cancer therapies may drive pharmaceutical firms to join forces, resultin in expanded market reach and prospects, for growth.

The increasing worldwide need for cancer treatments indicates a promising market opportunity. With changing consumer demands influenced by disease rates and awareness levels focusing on the use of Niraparib Tosylate Monohydrate, in treating ovarian cancer could lead to significant market growth.

Growth Opportunities in North America and Asia-Pacific

Asia Pacific Outlook

The Asia Pacific region presents a perspective on Niraparib Tosylate Monohydrate compared to other regions like the Western markets. Despite being in its stages of development in this region with countries such as India, China and Japan leading the way the market potential is immense. Driven by the rising instances of ovarian cancer and advancements in healthcare facilities the demand, for Niraparib Tosylate Monohydrate is steadily increasing.

North America Outlook

In North America's boundaries the popularity of Niraparib Tosylate Monohydrate has significantly increased due to the rising cases of cancer and the growing elderly population. The established healthcare system in the region and the increasing number of oncology clinical trials have also contributed to the growth of Niraparib Tosylate Monohydrate market. Its no surprise that there is competition in this region with pharmaceutical giants, like GSK and TESARO leading in the production and distribution of this cancer treatment drug. The main reason behind the growth of the market is the increasing use of Niraparib Tosylate Monohydrate, in treating recurring cases of ovarian and related cancers.

North America Outlook

In North America's boundaries the popularity of Niraparib Tosylate Monohydrate has significantly increased due to the rising cases of cancer and the growing elderly population. The established healthcare system in the region and the increasing number of oncology clinical trials have also contributed to the growth of Niraparib Tosylate Monohydrate market. Its no surprise that there is competition in this region with pharmaceutical giants, like GSK and TESARO leading in the production and distribution of this cancer treatment drug. The main reason behind the growth of the market is the increasing use of Niraparib Tosylate Monohydrate, in treating recurring cases of ovarian and related cancers.

Asia-Pacific Outlook

The Asia Pacific region presents a perspective on Niraparib Tosylate Monohydrate compared to other regions like the Western markets. Despite being in its stages of development in this region with countries such as India, China and Japan leading the way the market potential is immense. Driven by the rising instances of ovarian cancer and advancements in healthcare facilities the demand, for Niraparib Tosylate Monohydrate is steadily increasing.

Growth Opportunities in North America and Asia-Pacific

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : U.S., Germany, UK, Japan, China are expected to grow at 4.9% to 7.2% CAGR

2

Emerging Markets : Brazil, South Korea, South Africa are expected to grow at 8.6% to 10.3% CAGR

Market Analysis Chart

Niraparib Tosylate Monohydrate is experiencing a rise in demand within the pharmaceutical field due to its promising abilities in treating ovarian cancer. The increasing focus on advancements in oncology and the expanding number of patients needing treatment have contributed to this trend. Moreover the growing interest, in research and development efforts regarding targeted therapy has further boosted the market prospects of Niraparib Tosylate Monohydrate. Nonetheless this positive trajectory faces some challenges that need to be addressed.

Recent Developments and Technological Advancement

December 2024

Aurelius Pharma has revealed the opening of a facility specifically, for manufacturing Niraparib Tosylate Monohydrate to keep up with the increasing demand worldwide.

October 2024

Pharmax Ltd has received the light from the FDA for a novel treatment that combines Niraparib Tosylate Monohydrate to combat ovarian cancer effectively.

July 2024

Innovare Therapeutics has started conducting Phase III trials for a new treatment involving Niraparib Tosylate Monohydrate in individuals, with late stage prostate cancer.

Niraparib Tosylate Monohydrate has seen advancements in the oncology pharmaceutical industry as a key player, in treating ovarian cancer and other solid tumors worldwide.

Impact of Industry Transitions on the Niraparib Tosylate Monohydrate Market

As a core segment of the Pharmaceutical industry, the Niraparib Tosylate Monohydrate market develops in line with broader industry shifts. Over recent years, transitions such as Paradigm Shift in Cancer Therapies and Evolution in Pharmaceutical Manufacturing have redefined priorities across the Pharmaceutical sector, influencing how the Niraparib Tosylate Monohydrate market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Paradigm Shift in Cancer Therapies:

The medical field has seen a shift with the introduction of Niraparib Tosylate Monohydrate as a powerful treatment option for cancer patients. This compound has garnered attention in the treatment of cancer due to its promising results in enhancing survival rates and overall quality of life for individuals affected by the disease. For patients with BRCA mutations the advantages of using this compound are noteworthy and have sparked interest among researchers to explore its potential applications further. Its ability to hinder the repair of DNA damage and prevent growth positions it as a leading contender, in advanced treatment strategies. The emergence of Niraparib has led to a transition, from traditional cancer therapies to more precise and efficient approaches.

2

Evolution in Pharmaceutical Manufacturing:

The manufacturing of Niraparib Tosylate Monohydrate has led to changes in the pharmaceutical production industry well. This specific compound demands manufacturing methods and strict quality checks, which have prompted improvements and innovations, in pharmaceutical manufacturing procedures.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions , have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Niraparib Tosylate Monohydrate market, setting the stage for its future growth trajectory.

Impact of global events on parent industry growth from 2020 to 2030

Market Dynamics and Supply Chain

Driver: Rising Prevalence of Ovarian Cancer

The rise in cancer cases worldwide has also led to a significant market opportunity for Niraparib Tosylate Monohydrate. A specialized treatment for adult patients with recurrent ovarian cancer and related conditions like fallopian tube or primary peritoneal cancer in their maintenance therapy regimen. Data shows an increase in the number of ovarian cancer patients diagnosed and this has also created a greater need for effective treatment options such, as Niraparib Tosylate Monohydrate.
In the realm of cancer treatment technology advancements also play a role in boosting the demand for Niraparib Tosylate Monohydrate in the market scene. The progress in medicine and a deeper grasp of cancer biology have also spurred the creation of targeted treatments like Niraparib Tosylate Monohydrate. A prime illustration of success in this domain. Its ability to disrupt DNA repair processes within cells presents an encouraging approach, to impeding tumor growth; hence driving its market appeal further.

Restraint: Regulatory Hurdles

The primary market demand, for Niraparib Tosylate Monohydrate comes from the regulatory and approval processes in place. These processes typically necessitate an amount of safety and efficacy data gathered over multiple clinical trial phases that span several years and require substantial financial investments. The lengthy and costly approval process may impede the availability of Niraparib Tosylate Monohydrate in the market landscape thus impacting the overall market dynamics and product demand.

Challenge: Treatment Accessibility

Additionally the availability of treatment plans for patients can also serve as a factor to consider. Niraparib Tosylate Monohydrate represents a cancer therapy that is typically given in specialized medical facilities. Nevertheless not only all areas have access to these healthcare services or oncologists capable of administering the medication. Furthermore the significant expenses linked with the treatment may present a barrier for prospective patients leading to a decrease, in market demand overall.

Supply Chain Landscape

Raw Material Procurement

BASF

Dow Chemical Corporation

API Production

Lonza

Cipla

Formulation & Drug Production
GlaxoSmithKline / Pfizer
Distribution & Marketing
Eli Lilly / Novartis
Raw Material Procurement

BASF

Dow Chemical Corporation

API Production

Lonza

Cipla

Formulation & Drug Production

GlaxoSmithKline

Pfizer

Distribution & Marketing

Eli Lilly

Novartis

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Cancer Treatment
Pharmaceuticals
GlaxoSmithKline plc.
Developing cost-effective therapy regimens for improved patient outcomes
Research and Development (R&D)
Biotechnology
Zeal Medipharma
Investing in advanced research to explore additional potential cancer therapeutics
Manufacturing and Supply of Active Pharmaceutical Ingredients (APIs)
Chemical Industry
Fox Chemicals GmbH
Adhering to stringent quality control protocols to ensure high-quality, bio-effective APIs

Elevate your strategic vision with in-depth analysis of key applications, leading market players & their strategies. Report analyze industry leader's views & statements on Niraparib Tosylate Monohydrate market's present & future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Niraparib Tosylate Monohydrate in Oncological Therapies, Maintenance Therapy and Research & Development

Oncological Therapies

Niraparib Tosylate Monohydrate is commonly used in cancer treatment, for cancer patients to slow down the growth of cancer cells and improve outcomes and survival rates for patients undergoing treatment in this field of medicine.

Maintenance Therapy

Furthermore the significance of Niraparib Tosylate Monohydrate is evident in its application as a chemotherapy maintenance therapy strategy. It disrupts the processes of cancer cells which helps in reducing the chances of disease advancement or relapse. Consistent administration of this substance has shown promise in periods of remission effectively. Enterprises, like AstraZeneca dominate the market in this field utilizing the benefits of the compound for enhancing patients’ quality of life.

Research & Development

The substance is widely used in research and development environments well. Continuous studies investigating the advantages of Niraparib Tosylate Monohydrate in cancer treatment have resulted in its inclusion in clinical trials for variouss of cancer apart from ovarian cancer. Including breast and prostate cancers. Prominent research facilities around the world are examining its role in creating innovative treatments for these diseases. Companies like Merck & Co are achieving progress in this region while solidifying their position, in the market.

Niraparib Tosylate Monohydrate vs. Substitutes:
Performance and Positioning Analysis

Niraparib Tosylate Monohydrate stands distinct from its alternatives due to its superior efficacy in treating ovarian cancer, thus showcasing potential for monumental growth within the pharmaceutical industry

Niraparib Tosylate Monohydrate
  • Olaparib /
  • Rucaparib /
  • Veliparib
    Effective in disrupting tumor growth, extends progression-free survival
    The risk of severe side effects, high costs associated with treatment
    Improved patient quality of life, Reduced treatment side effects
    Reduced efficacy, Potential for resistance development

Niraparib Tosylate Monohydrate vs. Substitutes:
Performance and Positioning Analysis

Niraparib Tosylate Monohydrate

  • Effective in disrupting tumor growth, extends progression-free survival
  • The risk of severe side effects, high costs associated with treatment

Olaparib / Rucaparib / Veliparib

  • Improved patient quality of life, Reduced treatment side effects
  • Reduced efficacy, Potential for resistance development

Niraparib Tosylate Monohydrate stands distinct from its alternatives due to its superior efficacy in treating ovarian cancer, thus showcasing potential for monumental growth within the pharmaceutical industry

Loading...

Research Methodology

This market research methodology defines the Niraparib Tosylate Monohydrate market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Niraparib Tosylate Monohydrate across Chemotherapy, Maintenance Treatment, and Targeted Therapy Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as GlaxoSmithKline plc, Tesaro Inc., and Ziopharm Oncology Inc. by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Procurement, API Production, and Formulation & Drug Production. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Niraparib Tosylate Monohydrate segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Procurement (BASF, Dow Chemical Corporation), API Production (Lonza, Cipla), and Formulation & Drug Production. Our parallel substitute analysis examines Olaparib, Rucaparib, and Veliparib, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as GlaxoSmithKline plc, Tesaro Inc., and Ziopharm Oncology Inc., analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Niraparib Tosylate Monohydrate market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Niraparib Tosylate Monohydrate Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 1.7 billion
Revenue Forecast in 2034USD 3.3 billion
Growth RateCAGR of 7.5% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 20241.6 billion
Growth OpportunityUSD 1.7 billion
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD billion and Industry Statistics
Market Size 20241.6 billion USD
Market Size 20272.0 billion USD
Market Size 20292.3 billion USD
Market Size 20302.5 billion USD
Market Size 20343.3 billion USD
Market Size 20353.5 billion USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredProduct Form, Application, Distribution Channel, Purity Grade, Production Method
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledGlaxoSmithKline plc, Tesaro Inc., Ziopharm Oncology Inc., Medivation Inc., Clovis Oncology Inc, Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, Eisai Co. Ltd, Roche Holding AG, Bayer AG and Merck & Co. Inc.
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Niraparib Tosylate Monohydrate Market Size, Opportunities & Strategic Insights, by Product Form

4.1Powder
4.2Granule
4.3Tablet
Chapter 5

Niraparib Tosylate Monohydrate Market Size, Opportunities & Strategic Insights, by Application

5.1Chemotherapy
5.2Maintenance Treatment
5.3Targeted Therapy
5.4Others
Chapter 6

Niraparib Tosylate Monohydrate Market Size, Opportunities & Strategic Insights, by Distribution Channel

6.1Hospitals
6.2Pharmacies
6.3Online Retailers
Chapter 7

Niraparib Tosylate Monohydrate Market Size, Opportunities & Strategic Insights, by Purity Grade

7.198%-99%
7.299%-99.5%
7.399.5%-100%
Chapter 8

Niraparib Tosylate Monohydrate Market Size, Opportunities & Strategic Insights, by Production Method

8.1Synthesis
8.2Biosynthesis
Chapter 9

Niraparib Tosylate Monohydrate Market, by Region

9.1North America Niraparib Tosylate Monohydrate Market Size, Opportunities, Key Trends & Strategic Insights
9.1.1U.S.
9.1.2Canada
9.2Europe Niraparib Tosylate Monohydrate Market Size, Opportunities, Key Trends & Strategic Insights
9.2.1Germany
9.2.2France
9.2.3UK
9.2.4Italy
9.2.5The Netherlands
9.2.6Rest of EU
9.3Asia Pacific Niraparib Tosylate Monohydrate Market Size, Opportunities, Key Trends & Strategic Insights
9.3.1China
9.3.2Japan
9.3.3South Korea
9.3.4India
9.3.5Australia
9.3.6Thailand
9.3.7Rest of APAC
9.4Middle East & Africa Niraparib Tosylate Monohydrate Market Size, Opportunities, Key Trends & Strategic Insights
9.4.1Saudi Arabia
9.4.2United Arab Emirates
9.4.3South Africa
9.4.4Rest of MEA
9.5Latin America Niraparib Tosylate Monohydrate Market Size, Opportunities, Key Trends & Strategic Insights
9.5.1Brazil
9.5.2Mexico
9.5.3Rest of LA
9.6CIS Niraparib Tosylate Monohydrate Market Size, Opportunities, Key Trends & Strategic Insights
9.6.1Russia
9.6.2Rest of CIS
Chapter 10

Competitive Landscape

10.1Competitive Dashboard & Market Share Analysis
10.2Company Profiles (Overview, Financials, Developments, SWOT)
10.2.1GlaxoSmithKline plc
10.2.2Tesaro Inc.
10.2.3Ziopharm Oncology Inc.
10.2.4Medivation Inc.
10.2.5Clovis Oncology Inc
10.2.6Pfizer Inc.
10.2.7Novartis AG
10.2.8Bristol-Myers Squibb Company
10.2.9Eisai Co. Ltd
10.2.10Roche Holding AG
10.2.11Bayer AG
10.2.12Merck & Co. Inc.